Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
Glucotrack (Nasdaq: GCTK) named Usman Latif, MD, MBA to its clinical advisory team on October 29, 2025 to guide development of integrated glucose monitoring for painful diabetic neuropathy (PDN) and epidural monitoring.
Dr. Latif is an anesthesiologist and neuromodulation expert with academic appointments and clinical fellowships at institutions including Johns Hopkins, Harvard/Mass General, Yale, and University of Kansas. The company said it completed a long-term preclinical study showing feasibility and safety of epidural glucose monitoring and continues development of its implantable CBGM system with 3-year sensor longevity.
PDN affects roughly one-fifth of >38 million Americans with diabetes (~7 million people). The CBGM is an investigational device and Glucotrack highlighted regulatory, clinical trial, and financing risks.
Glucotrack (Nasdaq: GCTK) ha nominato Usman Latif, MD, MBA al suo team di consulenza clinica in data 29 ottobre 2025 per guidare lo sviluppo di monitoraggio integrato della glicemia per la neuropatia diabetica dolorosa (PDN) e per il monitoraggio epidurale.
Il dottor Latif è un anestesista ed esperto di neuromodulazione, con incarichi accademici e fellowships clinici in istituzioni tra cui Johns Hopkins, Harvard/Mass General, Yale e University of Kansas. L'azienda ha detto di aver completato uno studio preclinico a lungo termine che dimostra la fattibilità e la sicurezza del monitoraggio epidurale della glicemia e prosegue lo sviluppo del suo sistema CBGM impiantabile con una longevità del sensore di 3 anni.
La PDN colpisce circa un quinto di oltre 38 milioni di americani con diabete (circa 7 milioni di persone). Il CBGM è un dispositivo sperimentale e Glucotrack ha evidenziato rischi regolatori, di trial clinico e di finanziamento.
Glucotrack (Nasdaq: GCTK) nombró Usman Latif, MD, MBA a su equipo de asesoría clínica el 29 de octubre de 2025 para guiar el desarrollo de un monitoreo de glucosa integrado para la neuropatía diabética dolorosa (PDN) y el monitoreo epidural.
El Dr. Latif es anestesiólogo y experto en neuromodulación con nombramientos académicos y becas clínicas en instituciones que incluyen Johns Hopkins, Harvard/Mass General, Yale y University of Kansas. La empresa dijo haber completado un estudio preclínico a largo plazo que demuestra la viabilidad y seguridad del monitoreo epidural de glucosa y continúa el desarrollo de su sistema CBGM implantable con una longevidad del sensor de 3 años.
La PDN afecta aproximadamente a una quinta parte de más de 38 millones de estadounidenses con diabetes (alrededor de 7 millones de personas). El CBGM es un dispositivo en investigación y Glucotrack resaltó riesgos regulatorios, de ensayos clínicos y de financiamiento.
글루코트랙(나스닥: GCTK)은/는 2025년 10월 29일에 Usman Latif, MD, MBA를 임상 자문팀에 임명하여 고통성 당뇨병 신경병증(PDN) 및 경막외 모니터링을 위한 통합 혈당 모니터링 개발을 안내합니다.
라티프 박사는 존스 홉킨스, Harvard/Mass General, 예일, 캔자스 대학교 등 여러 기관에서 학술 직책과 임상 펠로우십을 가진 마취과 의사이자 신경조절 전문가입니다. 회사는 경막외 혈당 모니터링의 타당성과 안전성을 보여주는 장기간의 전임상 연구를 완료했고, 3년 센서 수명의 이식형 CBGM 시스템 개발을 계속하고 있다고 밝혔습니다.
PDN은 당뇨병을 가진 미국인 약 5분의 1 정도(>3,800만 명 중 약 700만 명)에 영향을 미칩니다. CBGM은 연구 중인 기기로, 글루코트랙은 규제, 임상시험 및 자금 조달 위험을 강조했습니다.
Glucotrack (Nasdaq : GCTK) a nommé Usman Latif, MD, MBA dans son équipe consultative clinique le 29 octobre 2025 pour guider le développement d'un monitorage intégré de la glycémie pour la neuropathie diabétique douloureuse (PDN) et le monitorage épidural.
Le Dr Latif est un anesthésiste et expert en neuromodulation avec des postes académiques et des bourses cliniques dans des institutions telles que Johns Hopkins, Harvard/Mass General, Yale et l'Université du Kansas. L'entreprise a déclaré avoir mené une étude préclinique à long terme démontrant la faisabilité et la sécurité du monitorage épidural de la glycémie et poursuit le développement de son système CBGM implantable avec une longévité du capteur de 3 ans.
La PDN affecte environ un cinquième des plus de 38 millions d'Américains diabétiques (~7 millions de personnes). Le CBGM est un dispositif expérimental et Glucotrack a souligné des risques réglementaires, les essais cliniques et le financement.
Glucotrack (Nasdaq: GCTK) hat Usman Latif, MD, MBA in sein klinisches Beratungsteam ernannt am 29. Oktober 2025, um die Entwicklung eines integrierten Glukose-Monitorings für schmerzhafte diabetische Neuropathie (PDN) und epiduralem Monitoring zu leiten.
Dr. Latif ist Anästhesist und Neuromodulations-Experte mit akademischen Positionen und klinischen Fellows an Institutionen wie Johns Hopkins, Harvard/Mass General, Yale und University of Kansas. Das Unternehmen teilte mit, dass es eine langfristige präklinische Studie abgeschlossen hat, die Machbarkeit und Sicherheit des epiduralen Glukosemessens zeigt, und setzt die Entwicklung seines implantierbaren CBGM-Systems mit einer Sensor-Langlebigkeit von 3 Jahren fort.
PDN betrifft ungefähr ein Fünftel der über 38 Millionen Amerikaner mit Diabetes (~7 Millionen Menschen). Der CBGM ist ein Untersuchungsgerät und Glucotrack hob regulatorische, klinische Studien- und Finanzierungsrisiken hervor.
Glucotrack (بورصة ناسداك: GCTK) عيّن فريقه الاستشاري السريري Usman Latif, MD, MBA في 29 أكتوبر 2025 لقيادة تطوير مراقبة الجلوكوز المتكاملة للاعتلال العصبي السكري المؤلم (PDN) والمراقبة فوق الجافية.
الدكتور لطيف هو طبيب تخدير وخبير في تنظيم التحفيز العصبي مع مناصب أكاديمية وزمالات سريرية في مؤسسات تشمل جونز هوبكنز، وهارفارد/ماساتجنرال، وييل، وجامعة كانساس. قالت الشركة إنها أكملت دراسة حيوانية طويلة الأجل تُظهر إمكانية وسمان الأمان لـ المراقبة فوق الجافية للجلوكوز وتواصل تطوير نظام CBGM القابل للزرع مع اعتماد استشعار لمدة 3 سنوات.
PDN تؤثر على نحو خُمُس من أكثر من 38 مليون أميركي مصاب بالسكري (حوالي 7 ملايين شخص). CBGM هو جهاز بحثي وركزت Glucotrack على مخاطر التنظيم، والتجارب السريرية، والتمويل.
Glucotrack (纳斯达克：GCTK) 于 2025年10月29日 任命 Usman Latif, MD, MBA 加入其临床咨询团队，以指导开发面向痛性糖尿病性神经病变（PDN）的综合血糖监测及硬膜外监测。
Latif 医生是一名麻醉科医生和神经调控专家，在 Johns Hopkins、Harvard/Mass General、Yale 与 Kansas 大学等机构担任学术职位并获得临床研究员头衔。公司表示已完成一项长期的前临床研究，显示硬膜外血糖监测的可行性与安全性，并将继续开发具备3年传感器寿命的可植入 CBGM 系统。
PDN 影响大约< b>五分之一的超过3800万糖尿病美国人（约< b>700万人）。CBGM 是一项研究用设备，Glucotrack 指出监管、临床试验及融资风险。
- Completed long-term preclinical study demonstrating epidural glucose feasibility and safety
- CBGM platform designed for 3-year sensor longevity
- Appointed Dr. Usman Latif to clinical advisory team on Oct 29, 2025
- CBGM is an investigational device limited to investigational use
- Company cites risk and uncertainty around timing of regulatory approvals
- Commercialization dependent on raising additional capital
Renowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring
RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack’s clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM).
“Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain management and product design will be invaluable as we advance integrated disease and device management solutions for PDN patients,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack.
Dr. Latif is an Associate Professor in the Department of Anesthesiology, Pain and Perioperative Medicine at The University of Kansas Medical Center and a Board-certified Anesthesiologist at The University of Kansas Health System. Dr. Latif earned his medical degree from the University of Kansas and completed residencies in Internal Medicine at Wake Forest University and Anesthesiology at Johns Hopkins Hospital. He then completed a fellowship in Interventional Pain Management at Harvard/Massachusetts General Hospital. He previously served as faculty at Yale University School of Medicine, where he worked as a Sub-Investigator at the Pfizer Clinical Research Unit. Dr. Latif also holds an MBA and earned a certificate in Value-Based Healthcare from Harvard Business School. He has published extensively in novel research, clinical guidelines, and textbook chapters. His research focuses on neuromodulation, innovative technology applications, AI, and data-driven medical advances.
“I’m excited to join Glucotrack’s clinical advisory team and help integrate glucose sensing directly into spinal cord stimulator leads,” said Dr. Usman Latif. “For patients with PDN, managing their condition often involves multiple devices and disjointed streams of information. Glucotrack's vision of integrating continuous glucose monitoring into proven pain management therapies like spinal cord stimulation could be a significant advancement in integrated care. It’s an honor to help guide the development of a technology that could simplify care, empower physicians with better data, and ultimately improve outcomes for these patients.”
PDN is a progressive neurological disorder that affects approximately one-fifth of the more than 38 million Americans with diabetes, equating to more than 7 million individuals.1,2 Its symptoms include pain and numbness in the feet, legs, and hands which can significantly impact patients’ quality of life and functional ability.3 Recently, Spinal Cord Stimulation (SCS) technology has been indicated as a treatment option providing significant long-term pain relief to these patients.4 A spinal cord stimulator is an implanted device, with electrodes placed in the epidural space, that sends low levels of electricity directly into the spinal cord to relieve pain.5 Glucotrack’s sensing technology has the potential to be integrated into existing SCS devices to measure epidural glucose in patients with PDN who decide to undergo SCS treatment.
Following Glucotrack's announcement in April 2024 of its expansion into epidural glucose monitoring, the Company has successfully completed a long-term preclinical study demonstrating the feasibility and safety of glucose monitoring in the epidural space. This technology builds on Glucotrack's glucose sensing capabilities developed for its CBGM platform.
1 Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–2224.
2 Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html
3 Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350-354. doi:10.1097/00002508-200211000-00002.
4 Erika A. Petersen, Thomas G. Stauss, James A. Scowcroft, Elizabeth S. Brooks, Judith L. White, Shawn M. Sills, Kasra Amirdelfan, Maged N. Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis G. Patterson, Kostandinos C. Tsoulfas, Michael J. Creamer, Vincent Galan, Richard H. Bundschu, Neel D. Mehta, Dawood Sayed, Shivanand P. Lad, David J. DiBenedetto, Khalid A. Sethi, Johnathan H. Goree, Matthew T. Bennett, Nathan J. Harrison, Atef F. Israel, Paul Chang, Paul W. Wu, Charles E. Argoff, Christian E. Nasr, Rod S. Taylor, David L. Caraway, Nagy A. Mekhail; Durability of High-Frequency 10-kHz Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy Refractory to Conventional Treatments: 12-Month Results From a Randomized Controlled Trial. Diabetes Care 5 January 2022; 45 (1): e3–e6. https://doi.org/10.2337/dc21-1813
5 Dydyk AM, Tadi P. Spinal Cord Stimulator Implant. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555994/
About Glucotrack, Inc.
Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is Usman Latif and why did Glucotrack (GCTK) appoint him on October 29, 2025?
What did Glucotrack announce about epidural glucose monitoring on October 29, 2025?
What is Glucotrack's CBGM sensor longevity and regulatory status (GCTK)?
How many Americans with diabetes are estimated to have painful diabetic neuropathy cited by Glucotrack?
How might Dr. Latif's appointment affect Glucotrack's product development and PDN strategy?
What risks did Glucotrack (GCTK) highlight related to its CBGM and epidural monitoring plans?
